鲁抗医药(600789.SH)：控股子公司的米诺地尔搽剂获得药品注册证书

Core Viewpoint - The company, LuKang Pharmaceutical (600789.SH), announced that its subsidiary, Shandong LuKang Pharmaceutical Group Saiter Co., Ltd., received a drug registration certificate from the National Medical Products Administration for Minoxidil topical solution, which is classified as a generic drug and has passed the consistency evaluation of quality and efficacy for generic drugs [1]. Group 1 - The drug Minoxidil is classified as a potassium channel opener and is primarily used for treating hypertension, but it also has the side effect of hypertrichosis [1]. - The U.S. company Upjohn conducted research on the adverse effects of Minoxidil and found that its topical solution is effective in treating hair loss [1]. - Minoxidil was approved by the U.S. FDA in September 1988 for the treatment of alopecia areata in men and chemotherapy-induced hair loss, with subsequent approvals for use in women and a higher concentration formulation for men [1]. Group 2 - Currently, there are various formulations of Minoxidil available in China, including topical solutions and tinctures, used for treating hair loss [1]. - The newly approved product is indicated for the treatment of male pattern baldness and alopecia areata [1].